Auranofin/Betamethasone Dipropionate

金诺芬/倍他米松二丙酸酯

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAuranofin/Betamethasone Dipropionate
Drug Alias Name倍他米松二丙酸酯/金诺芬Betamethasone Dipropionate/Auranofinauranofin + betamethasone dipropionateorgano-gold compound + steroidSorafin-P
ClassificationSmall molecules > Steroids
Mechanisms of ActionInhibitor of NF-kappa-B kinase (IKK) inhibitorsGlucocorticoid receptor agonists
TargetsGlucocorticoid receptorInhibitor of NF-kappa-B kinase (IKK)
Therapy Area/IndicationsPsoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes AuranofinBetamethasone Dipropionate
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesViralytics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesViralytics Ltd
Active IndicationsN/A
Inactive IndicationsPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A